These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 22939907)
1. Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel. Ben-Shimol S; Greenberg D; Givon-Lavi N; Elias N; Glikman D; Rubinstein U; Dagan R; Vaccine; 2012 Oct; 30(46):6600-7. PubMed ID: 22939907 [TBL] [Abstract][Full Text] [Related]
3. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148 [TBL] [Abstract][Full Text] [Related]
4. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490 [TBL] [Abstract][Full Text] [Related]
5. Evolving picture of invasive pneumococcal disease in massachusetts children: a comparison of disease in 2007-2009 with earlier periods. Yildirim I; Stevenson A; Hsu KK; Pelton SI Pediatr Infect Dis J; 2012 Oct; 31(10):1016-21. PubMed ID: 22673142 [TBL] [Abstract][Full Text] [Related]
6. Antibiotic resistance and serotype distribution of invasive pneumococcal diseases before and after introduction of pneumococcal conjugate vaccine in the Kingdom of Saudi Arabia (KSA). Shibl AM; Memish ZA; Al-Kattan KM Vaccine; 2012 Dec; 30 Suppl 6():G32-6. PubMed ID: 23228355 [TBL] [Abstract][Full Text] [Related]
7. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait. Mokaddas E; Albert MJ Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356 [TBL] [Abstract][Full Text] [Related]
8. Impact of PCV7/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: Comparison between meningitis and non-meningitis IPD. Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Miron D; Aviner S; Dagan R; Vaccine; 2016 Aug; 34(38):4543-4550. PubMed ID: 27475471 [TBL] [Abstract][Full Text] [Related]
9. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines. Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924 [TBL] [Abstract][Full Text] [Related]
10. Changes in the composition of the pneumococcal population and in IPD incidence in The Netherlands after the implementation of the 7-valent pneumococcal conjugate vaccine. Elberse KE; van der Heide HG; Witteveen S; van de Pol I; Schot CS; van der Ende A; Berbers GA; Schouls LM Vaccine; 2012 Dec; 30(52):7644-51. PubMed ID: 22521844 [TBL] [Abstract][Full Text] [Related]
11. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme. Ingels H; Rasmussen J; Andersen PH; Harboe ZB; Glismann S; Konradsen H; Hoffmann S; Valentiner-Branth P; Lambertsen L; Vaccine; 2012 Jun; 30(26):3944-50. PubMed ID: 22504662 [TBL] [Abstract][Full Text] [Related]
12. Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: A nationwide surveillance study. Regev-Yochay G; Paran Y; Bishara J; Oren I; Chowers M; Tziba Y; Istomin V; Weinberger M; Miron D; Temper V; Rahav G; Dagan R; Vaccine; 2015 Feb; 33(9):1135-42. PubMed ID: 25613717 [TBL] [Abstract][Full Text] [Related]
13. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Isaacman DJ; McIntosh ED; Reinert RR Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359 [TBL] [Abstract][Full Text] [Related]
14. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Black S; France EK; Isaacman D; Bracken L; Lewis E; Hansen J; Fireman B; Austrian R; Graepel J; Gray S; Klein NP Pediatr Infect Dis J; 2007 Sep; 26(9):771-7. PubMed ID: 17721369 [TBL] [Abstract][Full Text] [Related]
16. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children. van der Linden M; Weiß S; Falkenhorst G; Siedler A; Imöhl M; von Kries R Vaccine; 2012 Aug; 30(40):5880-5. PubMed ID: 22771186 [TBL] [Abstract][Full Text] [Related]
17. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Albrich WC; Baughman W; Schmotzer B; Farley MM Clin Infect Dis; 2007 Jun; 44(12):1569-76. PubMed ID: 17516400 [TBL] [Abstract][Full Text] [Related]
18. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). American Academy of Pediatrics Committee on Infectious Diseases Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180 [TBL] [Abstract][Full Text] [Related]
19. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies. Ben-Shimol S; Givon-Lavi N; Grisaru-Soen G; Megged O; Greenberg D; Dagan R; Vaccine; 2018 Aug; 36(36):5477-5484. PubMed ID: 28579230 [TBL] [Abstract][Full Text] [Related]